Kellie Ryan, MPH, discusses the importance of long-term follow-up with acalabrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
Kellie Ryan, MPH
Advertisement
Articles by Kellie Ryan, MPH
Advertisement
Latest Updated Articles
Long-Term Follow-Up of Acalabrutinib in Patients With MCL and CLLPublished: January 10th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5